Patents Assigned to Emory University
  • Chemokine CXCR4 receptor modulators and uses related thereto
    Patent number: 11497744
    Abstract: The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: November 15, 2022
    Assignee: Emory University
    Inventors: Dennis Liotta, Edgars Jecs, Robert James Wilson, Huy Hoang Nguyen, Michelle Bora Kim, Lawrence Wilson, Eric James Miller, Yesim Altas Tahirovic, Valarie Truax
  • Anatomical support systems, devices, and related methods
    Patent number: 11497647
    Abstract: The systems, devices and methods provide customizable and adjustable support to anatomical tissue or organs, such as pelvic, vaginal, uterine, cervical, bladder, rectal, among others, or any combination thereof. The anatomical support device may include a support member having a periphery that surrounds an opening. The support member may be configured to releasably and adjustably expand between one or more expanding states from a resting state and contract to the resting state. The support member may include a first portion and a second portion disposed along the periphery. Each portion may include a passage cross-sectional area and a wall thickness. The first wall thickness and/or the first passage cross-sectional area of the first portion may be different from the second wall thickness and/or the second passage cross-sectional area of the second portion.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: November 15, 2022
    Assignee: Emory University
    Inventors: Robert Kelley, Sruti Bheri, Esther Max-Onakpoya, Xiaoshan Shao, Alena Sim
  • SYSTEM AND METHOD FOR MITIGATING INTERNATIONAL REVENUE SHARE FRAUD
    Publication number: 20220360433
    Abstract: Aspects of the subject disclosure may include, for example, a non-transitory, machine-readable medium, comprising executable instructions that, when executed by a processing system including a processor, facilitate performance of operations including receiving a call; selecting a next carrier to handoff the call; generating a call data record (CDR) for the handoff to the next carrier; encrypting the CDR using a call encryption key, thereby creating an encrypted CDR; encrypting the encrypted CDR using a committee encryption key, thereby creating a double encrypted CDR; recording the double encrypted CDR to a blockchain; and sending the call encryption key to the next carrier. Other embodiments are disclosed.
    Type: Application
    Filed: May 10, 2021
    Publication date: November 10, 2022
    Applicants: AT&T Intellectual Property I, L.P., Emory University
    Inventors: Divesh Srivastava, Yaron Kanza, Tamraparni Dasu, Teddy Chu, Shuaicheng Ma, Li Xiong
  • Chimeric viruses encoding mutant zika virus envelope glycoproteins
    Patent number: 11491217
    Abstract: The present disclosure relates to Zika vaccines. In certain embodiments, this disclosure relates to vaccine compositions for use in methods of protecting a human subject against Zika disease or infection, wherein said composition comprises a vaccinal for Zika such as a live attenuated or inactivated chimeric Zika virus; live attenuated Zika virus; an inactivated Zika virus; a replication-defective pseudo-infectious Zika virus; a Zika virus-like particle (VLP), a Zika protein or combinations thereof. In certain embodiments, the Zika vaccinal comprises or encodes altered polypeptide sequences disclosed herein.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: November 8, 2022
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventor: Baek Kim
  • Compounds and compositions for ossification and methods related thereto
    Patent number: 11471461
    Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: October 18, 2022
    Assignees: Emory University, US Govt represented by Dept of Veterans Affairs
    Inventors: Scott D. Boden, Sreedhara Sangadala
  • Recombinant RSV with silent mutations, vaccines, and methods related thereto
    Patent number: 11471524
    Abstract: In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: October 18, 2022
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Martin L. Moore, Jia Meng, Anne Hotard, Elizabeth Littauer, Christopher Stobart
  • Redox dehydration coupling catalysts and methods related thereto
    Patent number: 11471868
    Abstract: This disclosure relates to synthetic coupling methods using catalytic molecules. In certain embodiments, the catalytic molecules comprise heterocyclic thiolamide, S-acylthiosalicylamide, disulfide, selenium containing heterocycle, diselenide compound, ditelluride compound or tellurium containing heterocycle.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: October 18, 2022
    Assignee: Emory University
    Inventors: Lanny Steven Liebeskind, Pavan Kumar Reddy Gangireddy
  • VIP antagonists and uses in treating cancer
    Patent number: 11471506
    Abstract: This disclosure relates to methods of treating cancer or viral infections comprising administering an effective amount of a VIP antagonist in combination with an immune check-point inhibitor to a subject in need thereof. In certain embodiments, the immune check-point inhibitor is an anti-PD1 or anti-PDL1 antibody.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: October 18, 2022
    Assignees: Emory University, Georgia Tech Research Corporation
    Inventors: Edmund K. Waller, Rebecca Pankove, Susan Thomas, Sruthi Ravindranathan
  • Particles for targeted delivery and uses in managing bleeding or blood clotting
    Patent number: 11464748
    Abstract: This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: October 11, 2022
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc., Georgia Tech Research Corporation, Chapman University
    Inventors: Wilbur A. Lam, Caroline Hansen, Yumiko Sakurai, Andrew Lyon
  • Antagonism of the VIP signaling pathway
    Patent number: 11464855
    Abstract: Inhibition of the VIP signaling pathway with VIP antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a VIP antagonist to a subject in combination with a cell. In certain embodiments, the subject is diagnosed with leukemia or lymphoma. In certain embodiments, the cell is a blood cell, bone marrow cell, leukocyte, T-cell, natural killer cell, a hematopoietic stem cell, a G-CSF mobilized or non-mobilized blood mononuclear cell.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: October 11, 2022
    Assignee: Emory University
    Inventors: Edmund K. Waller, Jian-Ming Li, Mohammad S. Hossain
  • Methods and systems for automatically detecting events based on ECG signals determined from compressed sensed measurements
    Patent number: 11457853
    Abstract: Techniques are provided for generating and processing compressed sensor data. Sensor signals can be collected using one or more sensors. The sensor signals can be compressed using a compression data structure. In some instances, the compressed signal corresponds to a sampling rate at or below the Nyquist sampling rate. The compressed signal can be compared to one or more templates. Events within the compressed signal can be detected and characterized based on the comparison.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: October 4, 2022
    Assignees: Emory University, Universita degli Studi di Udine
    Inventors: Giulia Di Poian, Roberto Rinaldo, Gari Clifford
  • Phosphoramidates for the treatment of hepatitis B virus
    Patent number: 11447518
    Abstract: Disclosed are compounds to the treatment of infectious diseases and methods of treating such diseases. The compounds are derivatives of clevudine.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: September 20, 2022
    Assignee: Emory University
    Inventors: Abel de la Rosa, Gregory R. Bluemling
  • Assays for detecting antibodies capable of mediating antibody-dependent cell-mediated cytotoxicity
    Patent number: 11402380
    Abstract: This disclosure relates to assays for detecting activating antibodies in a sample that are capable of antibody-dependent cell-mediated cytotoxicity. In certain embodiments, this disclosure relates to target cells comprising an antigen on the exterior of the cells and a luciferase inside the cells. In certain embodiments, the antigen is an Ebola-virus glycoprotein. In certain embodiments, this disclosure relates to detecting changes in chemiluminescence of the luciferase as an indication of activating antibodies in a sample capable of cell lysis when mixed with effector cells.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 2, 2022
    Assignee: Emory University
    Inventors: Paul Spearman, Karnail Singh, Xuemin Chen
  • PROGESTERONE ANALOGS AND USES RELATED THERETO
    Publication number: 20220235092
    Abstract: This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.
    Type: Application
    Filed: February 4, 2022
    Publication date: July 28, 2022
    Applicant: EMORY UNIVERSITY
    Inventors: David B. Guthrie, Mark A. Lockwood, Dennis C. Liotta, Michael G. Natchus, Donald G. Stein, Iqbal Sayeed
  • Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers
    Patent number: 11384106
    Abstract: This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes comprise 99mTc or Re. In certain embodiments, the ligands are substituted with a fluorine, a fluorine-18(F18) radioisotope, or other radionuclide.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: July 12, 2022
    Assignee: Emory University
    Inventors: Jeffrey Klenc, Malgorzata Lipowska, Andrew Taylor
  • Recombinant vector and expression system comprising a nucleic acid encoding a variable lymphocyte receptor (VLR)
    Patent number: 11384134
    Abstract: This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: July 12, 2022
    Assignee: Emory University
    Inventors: Brantley R. Herrin, Max Dale Cooper, Rudolf Ehrhardt
  • ASPARAGINE ENDOPEPTIDASE (AEP) INHIBITORS, COMPOSITIONS, AND USES RELATED THERETO
    Publication number: 20220213087
    Abstract: This disclosure relates to asparagine endopeptidase inhibitors and compositions and uses related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are useful for improving memory, treating or preventing cancer, neurodegenerative diseases, and cognitive disorders. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising an asparagine endopeptidase inhibitor and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 7, 2022
    Applicant: EMORY UNIVERSITY
    Inventor: Keqiang Ye
  • Uses of epithelial-to-mesenchymal inhibitors in generating pacemaker cells
    Patent number: 11371020
    Abstract: This disclosure relates to methods of generating pacemaker cells for use in therapeutic strategies that address a heart that beats abnormally. In certain embodiments, one mixes cells with an epithelial-to-mesenchymal transformation inhibitor in combination with a nucleic acid encoding a transcription factor such as a vector that encodes a transcription factor such as Tbx18 in operable combination with a eukaryotic promoter to produce pacemaker cells that are then transplanted into the heart.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: June 28, 2022
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventor: Hee Cheol Cho
  • Phosphoramidates for the treatment of hepatitis B virus
    Patent number: 11364257
    Abstract: Disclosed are compounds and compositions to the treatment of infectious diseases and methods of treating such diseases. The compounds and compositions include derivatives of clevudine. The compounds and compositions include derivatives of clevudine in combination with another antiviral agent. The compounds and compositions include derivatives of clevudine in combination with a phosphoramidate of lamivudine, adefovir, tenofovir, telbivudine, entecavir, or combinations thereof.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: June 21, 2022
    Assignee: Emory University
    Inventors: Abel De La Rosa, George Painter, Gregory R. Bluemling
  • Systems and methods for tissue treatment
    Patent number: 11357530
    Abstract: Systems and methods are configured to treat a tissue by automatically linearly oscillating an instrument into a target site. A system may include a body having a length and configured to receive a portion of the instrument guide member having an exposed end and/or an instrument. The system may further include an actuator member disposed within the body and configured to linearly oscillate the instrument within the instrument guide member a fixed distance past the exposed end. The systems and methods can increase patient comfort while empowering clinicians by simplifying interventions for musculoskeletal disorders.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: June 14, 2022
    Assignee: Emory University
    Inventors: Kenneth R. Mautner, Luka Grujic, Shawna M. Hagen, Brett Rogers, Jonathan Shaw